Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Rother

Showing results (111-120 of 122) with videos related to

Pageof 13
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|August 8, 2001
Inducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway diseaseA G Tesciuba, S Subudhi, R P Rother, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 8, 2000
Primary structure and functional characterization of a soluble, alternatively spliced form of B7-1S J Faas, M A Giannoni, A P Mickle, et al.
Molecular Immunology|November 1, 1995
In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5M J Evans, S A Rollins, D W Wolff, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 29, 2009
Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumabAndrew L Singer, Jamye E Locke, Zoe A Stewart, et al.
Molecular Immunology|December 1, 1996
Inhibition of complement activity by humanized anti-C5 antibody and single-chain FvT C Thomas, S A Rollins, R P Rother, et al.
The New England Journal of Medicine|February 6, 2004
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuriaPeter Hillmen, Claire Hall, Judith C W Marsh, et al.
Blood|May 10, 2005
Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibodyPaul J Tacken, I Jolanda M de Vries, Karlijn Gijzen, et al.
Blood|August 19, 2007
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuriaPeter Hillmen, Petra Muus, Ulrich Dührsen, et al.
Blood|December 7, 2007
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuriaRobert A Brodsky, Neal S Young, Elisabetta Antonioli, et al.
British Journal of Haematology|February 16, 2010
The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumabRichard Kelly, Louise Arnold, Stephen Richards, et al.
Pageof 13

Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
Journal of Immunology (Baltimore, Md. : 1950)|August 8, 2001
Inducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway diseaseA G Tesciuba, S Subudhi, R P Rother, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 8, 2000
Primary structure and functional characterization of a soluble, alternatively spliced form of B7-1S J Faas, M A Giannoni, A P Mickle, et al.
Molecular Immunology|November 1, 1995
In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5M J Evans, S A Rollins, D W Wolff, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 29, 2009
Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumabAndrew L Singer, Jamye E Locke, Zoe A Stewart, et al.
Molecular Immunology|December 1, 1996
Inhibition of complement activity by humanized anti-C5 antibody and single-chain FvT C Thomas, S A Rollins, R P Rother, et al.
The New England Journal of Medicine|February 6, 2004
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuriaPeter Hillmen, Claire Hall, Judith C W Marsh, et al.
Blood|May 10, 2005
Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibodyPaul J Tacken, I Jolanda M de Vries, Karlijn Gijzen, et al.
Blood|August 19, 2007
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuriaPeter Hillmen, Petra Muus, Ulrich Dührsen, et al.
Blood|December 7, 2007
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuriaRobert A Brodsky, Neal S Young, Elisabetta Antonioli, et al.
British Journal of Haematology|February 16, 2010
The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumabRichard Kelly, Louise Arnold, Stephen Richards, et al.
Pageof 13